Z-Basivarsen Delivers Durable One-Year Functional Gains in DM1, Separating From Natural History
DYN sits 32% above its 52-week low of $11.92.
Summary
One-year ACHIEVE trial data show z-basivarsen produced durable functional gains in DM1 patients, including divergence from a natural history cohort across strength and ambulation measures. Topline data from the registrational expansion cohort remain on track for Q1 2027.
Key Events · Product Development and Regulatory · DYN
-
One-Year Efficacy Data Show Durable Gains
In the pooled dose group (N=25-26), vHOT improved by 3.2 seconds at 6 months versus a 0.4-second worsening on placebo. At 12 months, QMT total and hand grip each improved 4.8% predicted, 5xSTS improved 1.2 seconds, and 10MWR improved 0.3 seconds.
-
First Divergence From Natural History
Z-basivarsen-treated participants diverged from a propensity-matched END-DM1 cohort (N=41-46) on QMT total, hand grip, and 10MWR at 12 months. This is the first time Dyne has shown separation from natural disease progression, not just placebo.
-
MDHI Exceeds MCID
MDHI total score improved 25.2% from baseline in the pooled dose group, exceeding the minimal clinically important difference and diverging from an unmatched natural history cohort (N=410), including improvements across six CNS-related subscales.
-
Registrational Cohort Baseline Set
The 71-participant ACHIEVE REC has a mean baseline vHOT of 8.3 seconds (SD 6.0). Topline data are expected in Q1 2027 to support a potential BLA submission for U.S. Accelerated Approval in Q3 2027.
Analysis · DYN · Life Sciences
One-year data from the ACHIEVE Phase 1/2 trial show that z-basivarsen produced sustained functional improvement across myotonia, strength, motor function, and patient-reported outcomes in myotonic dystrophy type 1. In the pooled dose group (N=25-26), vHOT improved by 3.2 seconds at 6 months versus a 0.4-second worsening on placebo, and at 12 months the treated group diverged from a propensity-matched natural history cohort on QMT total, hand grip, and 10-meter walk/run. MDHI total score improved 25.2%, exceeding the minimal clinically important difference. The fully enrolled registrational expansion cohort (N=71) has a mean baseline vHOT of 8.3 seconds, setting the stage for the Q1 2027 topline readout that could support a BLA submission for U.S. Accelerated Approval in Q3 2027. Safety remained favorable with no related serious adverse events. This marks the first time Dyne has shown divergence from natural history controls, not just placebo, strengthening the case that z-basivarsen modifies disease course rather than merely stabilizing symptoms.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37% of the 992 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DYN was trading at $15.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3B. The 52-week trading range was $11.92 to $27.31. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.